The third dataset included 626 young women with ovarian cancer, providing data on age, nulliparity, contraceptive use, menopause, family history, full-term pregnancies, obesity, metastasis, lymph node status, PIK3CA and TP53 mutations, tumor size, lymph nodes, histology, vascular invasion, grade, adjuvant chemotherapy, radiotherapy, hormone therapy, and progression. This evidence concerns the gene TP53 and ovarian carcinoma.